AstraZeneca announces several non-executive moves
pharmafile | March 1, 2012 | Appointment | Business Services, Manufacturing and Production, Research and Development, Sales and Marketing | AstraZeneca, appointments
AstraZeneca has announced that Leif Johansson is set to be elected as a non-executive director in April, with the intention that he will be appointed non-executive chairman of the board with effect from September.
Louis Schweitzer intends to retire from the board as chairman and as a director.
In addition, Graham Chipchase and Geneviève Berger will be proposed to shareholders for election as non-executive directors in April.
Michele Hooper intends to retire from the board in the same month after nine years’ service as a non-executive director. She is currently senior independent non-executive director, chairman of the audit committee and a member of the nomination and governance committee.
Also John Varley will take over as senior independent non-executive director. He will remain chairman of the remuneration committee and a member of the nomination and governance committee.
Rudy Markham will become chairman of the audit committee and will join the nomination and governance committee, remaining as a member of the remuneration committee.
Also in April Johansson will join the nomination and governance committee; Chipchase will join the audit committee; and Berger will become a member of the science committee.
Related Content

NICE recommends Benralizumab for Rare Form of Vasculitis
The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s benralizumab (Fasenra) as …

NICE approves AstraZeneca’s dual immunotherapy for advanced liver cancer
AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence …

Purpose and people: the enduring power of brand and the evolution of employer identity
Two decades ago, terms like purpose and people were rarely at the forefront of branding …






